The Medicines and Healthcare Products Regulatory Agency (MHRA) London has announced that the product information for daratumumab will be updated to include the risk of reactivation of hepatitis B virus (HBV).
source https://www.pharmatutor.org/pharma-news/2020/daratumumab-involved-in-risk-of-reactivation-of-hepatitis-b-virus
No comments:
Post a Comment